A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of LC002, a DermaVir Vaccine, HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART).

Trial Profile

A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of LC002, a DermaVir Vaccine, HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs LC 002 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2013 Results published in JAIDS.
    • 22 May 2012 Actual patient number changed from 26 to 28 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top